IP Library Granted Patent US 8,754,042
Granted Patent B2
US 8,754,042 · App. 13/574,124 · Granted Jun 17, 2014

Oligopeptide compounds and uses thereof

Inventor: Lars Prestegarden (Bergen, NO)
Assignee: Cytovation AS
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,754,042
App. No.
13/574,124
Granted
Jun 17, 2014
Kind
B2
Abstract

The present invention relates to novel agents, pharmaceutical compositions containing them, and their use in therapy, particularly anti-microbial and anti-cancer therapy. In particular, the present invention relates to novel peptide-based compounds based on SEQ ID NO:40 which have surprisingly been shown to have inhibitory effects on the growth and/or viability of cells, particularly bacterial and cancer cells. Also provided are therapeutic and non-therapeutic methods which comprise the use of peptides of the invention.

Claims (17)

1. An oligopeptidic compound comprising:

(i) the amino acid sequence YGRKKRRQRRRGKTLRVAKAIYKRYIE (SEQ ID NO: 40); or

(ii) an amino acid sequence having at least 95% sequence identity to the sequence of SEQ ID NO: 40;

wherein the compound has activity in inhibiting the growth and/or viability of bacterial cells and/or cancer cells selected from the group consisting of brain cancer cells, breast cancer cells, melanoma cells, neuroblastoma cells, and sarcoma cells.

2. An oligopeptidic compound comprising the amino acid sequence YGRKKRRQRRRGKTLRVAKAIYKRYIE (SEQ ID NO: 40).

3. The oligopeptidic compound of claim 1 , wherein the oligopeptidic compound comprises one or more D-amino acids.

4. The oligopeptidic compound of claim 3 , wherein the oligopeptidic compound contains all D-amino acids.

5. The oligopeptidic compound of claim 1 , wherein the oligopeptidic compound has one or more of the following properties:

a) a net charge at pH 7.0 of 10-13,

b) a pl of 12 to 13;

c) an average hydrophilicity of 0.7 to 1.0 and/or

d) a ratio of hydrophilic residues/total number of residues of 45-60%.

6. A pharmaceutical composition comprising the oligopeptidic compound of claim 1 and a pharmaceutically acceptable excipient.

7. A kit comprising the oligopeptidic compound of claim 1 or the pharmaceutical composition of claim 6 and a second therapeutically active agent, wherein the second therapeutically active agent is a chemotherapy agent, an anti-neoplastic agent, an antibiotic, an antiviral agent, or an antifungal agent.

8. The oligopeptidic compound of claim 2 , wherein the oligopeptidic compound comprises one or more D-amino acids.

9. A pharmaceutical composition comprising the oligopeptidic compound of claim 2 and a pharmaceutically acceptable excipient.

10. A kit comprising the oligopeptidic compound of claim 2 or the pharmaceutical composition of claim 9 and a second therapeutically active agent, wherein the second therapeutically active agent is a chemotherapy agent, an anti-neoplastic agent, an antibiotic, an antiviral agent, or an antifungal agent.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED AT REEL: 65446 FRAME: 212. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded May 14, 2025
From: CYTOVATION AS
To: CYTOVATION ASA
Reel/Frame 071279/0920 →
CHANGE OF NAME Recorded Nov 2, 2023
From: CYTOVATION AS
To: CYTOVATION ASA
Reel/Frame 065446/0212 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2012
From: PRESTEGARDEN, LARS
To: CYTOVATION AS
Reel/Frame 029152/0649 →
Priority Claims (1)
GB 1001602.0 · Feb 1, 2010 · national
Continuity (1)
Related Publication 20130023461A1 · Jan 24, 2013